Align Technology, Inc.

NasdaqGS:ALGN Stock Report

Market Cap: US$15.8b

Align Technology Valuation

Is ALGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALGN ($211.06) is trading below our estimate of fair value ($247.18)

Significantly Below Fair Value: ALGN is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALGN?

Key metric: As ALGN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ALGN. This is calculated by dividing ALGN's market cap by their current earnings.
What is ALGN's PE Ratio?
PE Ratio35.7x
EarningsUS$441.57m
Market CapUS$15.76b

Price to Earnings Ratio vs Peers

How does ALGN's PE Ratio compare to its peers?

The above table shows the PE ratio for ALGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.5x
SOLV Solventum
16x6.0%US$11.5b
COO Cooper Companies
47.5x19.3%US$18.6b
MMSI Merit Medical Systems
47.7x14.2%US$5.7b
HAE Haemonetics
30.6x24.3%US$3.8b
ALGN Align Technology
35.7x17.5%US$15.8b

Price-To-Earnings vs Peers: ALGN is expensive based on its Price-To-Earnings Ratio (35.7x) compared to the peer average (35.5x).

Price to Earnings Ratio vs Industry

How does ALGN's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
0.9xn/aUS$8.08m
PAVM PAVmed
0.4x-90.0%US$6.39m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
No more companies available in this PE range
ALGN 35.7xIndustry Avg. 35.2xNo. of Companies9PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ALGN is expensive based on its Price-To-Earnings Ratio (35.7x) compared to the US Medical Equipment industry average (35.2x).

Price to Earnings Ratio vs Fair Ratio

What is ALGN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALGN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.7x
Fair PE Ratio36.2x

Price-To-Earnings vs Fair Ratio: ALGN is good value based on its Price-To-Earnings Ratio (35.7x) compared to the estimated Fair Price-To-Earnings Ratio (36.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALGN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$211.06
US$264.08
+25.1%
11.7%US$320.00US$206.00n/a14
Dec ’25US$232.77
US$261.24
+12.2%
12.1%US$320.00US$200.00n/a13
Nov ’25US$208.58
US$261.24
+25.2%
12.1%US$320.00US$200.00n/a13
Oct ’25US$245.35
US$287.01
+17.0%
14.1%US$350.00US$215.00n/a13
Sep ’25US$237.22
US$287.01
+21.0%
14.1%US$350.00US$215.00n/a13
Aug ’25US$228.33
US$299.69
+31.3%
13.6%US$353.99US$215.00n/a13
Jul ’25US$238.64
US$333.43
+39.7%
11.8%US$400.00US$250.00n/a14
Jun ’25US$257.21
US$341.64
+32.8%
11.7%US$400.00US$250.00n/a14
May ’25US$284.52
US$336.55
+18.3%
12.0%US$400.00US$250.00n/a15
Apr ’25US$319.65
US$310.15
-3.0%
13.4%US$355.00US$215.00n/a15
Mar ’25US$300.01
US$309.14
+3.0%
13.0%US$350.00US$215.00n/a15
Feb ’25US$273.38
US$308.36
+12.8%
13.3%US$344.00US$215.00n/a14
Jan ’25US$274.00
US$277.58
+1.3%
19.9%US$344.00US$180.00n/a14
Dec ’24US$220.45
US$278.36
+26.3%
19.7%US$378.00US$180.00US$232.7714
Nov ’24US$183.21
US$278.36
+51.9%
19.7%US$378.00US$180.00US$208.5814
Oct ’24US$305.32
US$393.31
+28.8%
11.7%US$450.00US$270.00US$245.3513
Sep ’24US$374.90
US$393.31
+4.9%
11.7%US$450.00US$270.00US$237.2213
Aug ’24US$376.62
US$385.25
+2.3%
11.2%US$440.00US$270.00US$228.3312
Jul ’24US$353.64
US$354.91
+0.4%
13.9%US$420.00US$225.00US$238.6411
Jun ’24US$297.20
US$354.91
+19.4%
13.9%US$420.00US$225.00US$257.2111
May ’24US$317.33
US$354.91
+11.8%
13.9%US$420.00US$225.00US$284.5211
Apr ’24US$334.14
US$334.27
+0.04%
16.7%US$420.00US$190.00US$319.6511
Mar ’24US$308.53
US$333.70
+8.2%
17.5%US$420.00US$190.00US$300.0110
Feb ’24US$282.53
US$241.00
-14.7%
20.5%US$314.00US$160.00US$273.3810
Jan ’24US$210.90
US$250.00
+18.5%
25.9%US$375.00US$160.00US$274.0011
Dec ’23US$201.77
US$250.00
+23.9%
25.9%US$375.00US$160.00US$220.4511

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:32
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Align Technology, Inc. is covered by 49 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Ishan MajumdarBaptista Research
Charley JonesBarrington Research Associates, Inc.